FACTS vs OPINIONS: There are certain facts that we know from IPIX’s PRs and financial statements. Everything outside of IPIX’s sponsored information is purely speculation and is based on someone’s personal opinion. IPIX’s last few PRs have included surprises of a European Subsidiary, a Term Sheet for two instances of B-IBD and an update of selecting a drug formulation company while attending the Digestive Disease Week Conference. No one saw these PR’s coming which tells you that IPIX management is tightly guarded over material information until the information comes out publicly. IPIX has also proven that they can PR either anticipated or in many cases totally unanticipated material information at any time. Only Leo Ehrlich and Dr. Bertolino know what is about to be announced on any given day.
With the above as a given, the following is JMHO based on trying to connect the dots. The original Term Sheet signed last August included B-OM and B-IBD. At some point since last August’s Term Sheet I am speculating that Leo decided that the Sum of All Parts of Brilacidin was greater than the Whole. We have to remember last August there were somewhere around 20 NDA’s signed with Big Pharma. Leo IMO may have figured during the course of negotiations that he wasn’t getting maximum value for shareholders by trying to keep Brilacidin under a single umbrella agreement with one Big Global Pharm (BGP).
For the sake of example let’s pretend that there is a large BGP that has a strategic direction to grow their offerings in their GI Division. Let’s call them BGP-GI and they are very interested in B-IBD and value it quite highly as a means to grab a significant piece of a $48B market. BGP-GI may not however see B-OM as a fit for their organizational structure but make an initial offer encompassing all of Brilacidin applications and instances. Now let’s assume there is another BGP that has an extremely focused effort in growing their Cancer Division and B-OM fits perfectly as part of their portfolio. They have a common vision with IPIX to get B-OM through phase 3 and to make B-OM the standard treatment to prevent and treat Oral Mucositis. They may even have a strong interest in Kevetrin and could very well be a serious suitor for a separate future Term Sheet and License Deal for Kevetrin as the science advances. We will call these guys BGP-CD but they may however not see the IBD market as a strategic fit to their organizational direction. It doesn’t really matter if BGP-GI and BGP-CD are 2 separate divisions within the same BGP or if they are 2 completely different BGP’s. The point is by splitting B-OM and B-IBD into 2 separate deals, IPIX will maximize Brilacidin revenue and therefore maximize shareholder value. Also note that dermatitis and ABSSI could also be completely separate future license deals. IPIX could contractually separate worldwide rights of Brilacidin by instance, targeted area, geographic area and delivery mechanism. For example crystalized sachet formulations could be specific to B-OM as an oral rinse. ABSSSI could be strictly IV based. Dermatitis may be primarily a topical cream. There could be an oral pill based delivery system that could overlap targeted instances but that could be handled contractually which is above my pay grade. We could also see a BGP rename Brilacidin to distinguish it as part of their portfolio and/or target market.
There are MANY possible scenarios of how Brilacidin will be licensed and how many deals will happen and when they will happen. We can all have a WAG at how this will shake out but I believe the end result will be in shareholder’s best interest with Leo maximizing Brilaciidin and eventually Kevetrin revenue and license potential. IPIX’s FIRST deal will accelerate science advancement and eliminate the need for any additional dilution. As has been stated many times the law of supply and demand will eventually overtake the temporary control the criminals have over IPIX SP at this time. IPIX will be a wealth creator for patient investors IMO.
With the above as a given, the following is JMHO based on trying to connect the dots. The original Term Sheet signed last August included B-OM and B-IBD. At some point since last August’s Term Sheet I am speculating that Leo decided that the Sum of All Parts of Brilacidin was greater than the Whole. We have to remember last August there were somewhere around 20 NDA’s signed with Big Pharma. Leo IMO may have figured during the course of negotiations that he wasn’t getting maximum value for shareholders by trying to keep Brilacidin under a single umbrella agreement with one Big Global Pharm (BGP).
For the sake of example let’s pretend that there is a large BGP that has a strategic direction to grow their offerings in their GI Division. Let’s call them BGP-GI and they are very interested in B-IBD and value it quite highly as a means to grab a significant piece of a $48B market. BGP-GI may not however see B-OM as a fit for their organizational structure but make an initial offer encompassing all of Brilacidin applications and instances. Now let’s assume there is another BGP that has an extremely focused effort in growing their Cancer Division and B-OM fits perfectly as part of their portfolio. They have a common vision with IPIX to get B-OM through phase 3 and to make B-OM the standard treatment to prevent and treat Oral Mucositis. They may even have a strong interest in Kevetrin and could very well be a serious suitor for a separate future Term Sheet and License Deal for Kevetrin as the science advances. We will call these guys BGP-CD but they may however not see the IBD market as a strategic fit to their organizational direction. It doesn’t really matter if BGP-GI and BGP-CD are 2 separate divisions within the same BGP or if they are 2 completely different BGP’s. The point is by splitting B-OM and B-IBD into 2 separate deals, IPIX will maximize Brilacidin revenue and therefore maximize shareholder value. Also note that dermatitis and ABSSI could also be completely separate future license deals. IPIX could contractually separate worldwide rights of Brilacidin by instance, targeted area, geographic area and delivery mechanism. For example crystalized sachet formulations could be specific to B-OM as an oral rinse. ABSSSI could be strictly IV based. Dermatitis may be primarily a topical cream. There could be an oral pill based delivery system that could overlap targeted instances but that could be handled contractually which is above my pay grade. We could also see a BGP rename Brilacidin to distinguish it as part of their portfolio and/or target market.
There are MANY possible scenarios of how Brilacidin will be licensed and how many deals will happen and when they will happen. We can all have a WAG at how this will shake out but I believe the end result will be in shareholder’s best interest with Leo maximizing Brilaciidin and eventually Kevetrin revenue and license potential. IPIX’s FIRST deal will accelerate science advancement and eliminate the need for any additional dilution. As has been stated many times the law of supply and demand will eventually overtake the temporary control the criminals have over IPIX SP at this time. IPIX will be a wealth creator for patient investors IMO.
21
